Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)
Status:
Completed
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
Natural history research in Multiple Sclerosis (MS) suggests that risk of relapses and new
Magnetic Resonance Imaging (MRI) changes diminish significantly as people age, especially in
MS patients 55 or older. Thus, the need to continue MS medicines that reduce relapses and new
MRI lesions may also decrease as people age, especially in those who have not had relapses or
MRI scan changes for prolonged times. This study plans to learn more about the safety of
stopping MS medication in this population, as compared to continuing on the medication.
Phase:
Phase 4
Details
Lead Sponsor:
University of Colorado, Denver
Collaborators:
National Multiple Sclerosis Society Patient-Centered Outcomes Research Institute University of Alabama at Birmingham